Flow diversion of cerebral aneurysms in Type I osteogenesis imperfecta: A case report of the first two treatments in humans.
David A ZarrinJessica K CamposBenjamen M MeyerAlexander S HimsteadFahad LaghariJonathan C Collard de BeaufortKiarash GolshaniNarlin B BeatyMatthew T BenderGeoffrey P ColbyAlexander L CoonPublished in: SAGE open medical case reports (2024)
Osteogenesis imperfecta (OI) predisposes individuals to easy bone fracture, vessel fragility, and platelet dysfunction. We report the first known case of neurointerventional treatment with flow diversion of intracranial aneurysms in a patient with OI. A 62 year-old female with known OI Type I, history of >40 lifetime bone fractures and hypertension, underwent workup for transient ischemic attacks revealing a 4-mm right A1 segment aneurysm in 2016. Perioperative dual antiplatelet therapy was aspirin 81 mg and clopidogrel 37.5 mg daily. Tri-axial access was utilized to deploy a 3.5 × 16-mm Pipeline Flex device without complication. Two-month follow-up revealed Raymond I (O'Kelly Marotta I) obliteration of the aneurysm. Five-year follow-up revealed a de novo left-sided 3-mm A1-A2 junction aneurysm. A 4 × 12-mm Surpass Evolve was placed without complication. Six-month follow-up revealed Raymond I (O'Kelly Marotta I) obliteration of the second aneurysm. The patient remained asymptomatic at all follow-up visits.
Keyphrases
- antiplatelet therapy
- coronary artery
- acute coronary syndrome
- percutaneous coronary intervention
- bone regeneration
- single cell
- abdominal aortic aneurysm
- case report
- bone mineral density
- cerebral ischemia
- blood pressure
- cardiac surgery
- robot assisted
- low dose
- physical activity
- coronary artery disease
- type diabetes
- cardiovascular disease
- combination therapy
- blood brain barrier
- body composition
- atrial fibrillation
- bone loss